Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
covid-19 vaccine (chadox1-s [recombinant])
- Development stage
- Discontinued
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx1-S-nCoV-19 (AZD1222) is a replication-deficient chimpanzee adenoviral vector-based vaccine developed by the University of Oxford and AstraZeneca for the prevention of COVID-19. The vaccine utilizes the ChAdOx1 vector, derived from chimpanzee adenovirus Y25, to deliver the genetic sequence encoding the full-length, codon-optimized spike (S) glycoprotein of SARS-CoV-2. Upon intramuscular administration, the vector enters host cells via the coxsackievirus and adenovirus receptor (CAR) and drives the local expression of the spike protein, which subsequently stimulates neutralizing antibody and cellular immune responses. Marketed under the brand names Vaxzevria and Covishield, the vaccine was widely deployed globally during the COVID-19 pandemic but was commercially withdrawn in 2024.
- Brand names
- CovishieldVaxzevria
- Other names
- AstraZeneca COVID-19 VaccineCOVID-19 Vaccine AstraZenecaCOVID19 Vaccine AstraZenecaCOVID 19 Vaccine AstraZenecaOxford-AstraZeneca COVID-19 VaccineOxford-AstraZeneca vaccinesars-cov-2 (covid-19) chadox1 vaccine, recombinant
02
Targets
CXADR (Coxsackievirus and adenovirus receptor)
Beyond the preview
Go deeper on covid-19 vaccine (chadox1-s [recombinant]).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on covid-19 vaccine (chadox1-s [recombinant]).